TY - JOUR
T1 - Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA
T2 - A potential candidate for overcoming multi-drug resistance
AU - Ran, Rui
AU - Liu, Yayuan
AU - Gao, Huile
AU - Kuang, Qifang
AU - Zhang, Qianyu
AU - Tang, Jie
AU - Huang, Kai
AU - Chen, Xiaoxiao
AU - Zhang, Zhirong
AU - He, Qin
N1 - Funding Information:
This work was funded by the National Natural Science Foundation of China ( 81373337 ) and the National Basic Research Program of China (973 Program, 2013CB932504 ).
Publisher Copyright:
© 2014 Elsevier B.V. All rights reserved.
PY - 2014/12/30
Y1 - 2014/12/30
N2 - RNA interference is an effective method to achieve highly specific gene regulation. However, the commonly used cationic liposomes have poor biocompatibility, which may lead to systematic siRNA delivery of no avail. PEGylation is a good strategy in shielding the positive charge of cationic liposomes, but the enhanced serum stability is often in company with compromised cellular uptake and endosome escape. In this study, PEG was covalently linked to negatively charged hyaluronic acid and it was used to coat the liposome-siRNA nanoparticles. The resulting PEG-HA-NP complex had a diameter of 188.6 ± 10.8 nm and a dramatically declined zeta-potential from +34.9 ± 4.0 mV to -18.2 ± 2.2 mV. Owing to the reversed surface charge, PEG-HA-NP could remain stable in fetal bovine serum (FBS) to up to 24 h. In contrast with normal PEGylation, hyaluronic acid and PEG co-modified PEG-HA-NP provided comparable cellular uptake and P-glycoprotein downregulation efficacy in MCF-7/ADR cells compared with Lipofectamine RNAiMAX and naked NP regardless of its anionic charged surface. Because of its good biocompatibility in serum, PEG-HA-NP possessed the best tumor accumulation, cellular uptake and subsequently the strongest P-glycoprotein silencing capability in tumor bearing mice compared with naked NP and HA-NP after i.v. injection, with a 34% P-glycoprotein downregulation. Therefore, PEG-HA coated liposomal complex was demonstrated to be a promising siRNA delivery system in adjusting solid tumor P-glycoprotein expression, which may become a potential carrier in reversing MDR for breast cancer therapy.
AB - RNA interference is an effective method to achieve highly specific gene regulation. However, the commonly used cationic liposomes have poor biocompatibility, which may lead to systematic siRNA delivery of no avail. PEGylation is a good strategy in shielding the positive charge of cationic liposomes, but the enhanced serum stability is often in company with compromised cellular uptake and endosome escape. In this study, PEG was covalently linked to negatively charged hyaluronic acid and it was used to coat the liposome-siRNA nanoparticles. The resulting PEG-HA-NP complex had a diameter of 188.6 ± 10.8 nm and a dramatically declined zeta-potential from +34.9 ± 4.0 mV to -18.2 ± 2.2 mV. Owing to the reversed surface charge, PEG-HA-NP could remain stable in fetal bovine serum (FBS) to up to 24 h. In contrast with normal PEGylation, hyaluronic acid and PEG co-modified PEG-HA-NP provided comparable cellular uptake and P-glycoprotein downregulation efficacy in MCF-7/ADR cells compared with Lipofectamine RNAiMAX and naked NP regardless of its anionic charged surface. Because of its good biocompatibility in serum, PEG-HA-NP possessed the best tumor accumulation, cellular uptake and subsequently the strongest P-glycoprotein silencing capability in tumor bearing mice compared with naked NP and HA-NP after i.v. injection, with a 34% P-glycoprotein downregulation. Therefore, PEG-HA coated liposomal complex was demonstrated to be a promising siRNA delivery system in adjusting solid tumor P-glycoprotein expression, which may become a potential carrier in reversing MDR for breast cancer therapy.
KW - Cationic liposome
KW - P-glycoprotein downregulation
KW - PEGylated hyaluronic acid
KW - siRNA delivery
KW - Tumor targeting delivery
UR - http://www.scopus.com/inward/record.url?scp=84910011417&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2014.11.012
DO - 10.1016/j.ijpharm.2014.11.012
M3 - Article
C2 - 25448564
AN - SCOPUS:84910011417
SN - 0378-5173
VL - 477
SP - 590
EP - 600
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
IS - 1-2
ER -